Patients with p-p70S6K negative tumors derived significant benefit from tamoxifen ( HR 0.24 , P < 0.0001 ) , while patients whose tumor did express p-p70S6K did not ( HR = 1.02 , P = 0.95 ) , P for interaction 0.004 .